VI
VRTX icon

Vestcor Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Vestcor Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Sell
27,242
-6,777
-20% -$3M 0.33% 67
2026
Q1 		$15.2M Sell
34,019
-2,671
-7% -$1.25M 0.42% 60
2025
Q4 		$16.6M Buy
36,690
+1,424
+4% +$614K 0.47% 46
2025
Q3 		$13.8M Buy
35,266
+3,778
+12% +$1.58M 0.41% 56
2025
Q2 		$14M Sell
31,488
-653
-2% -$301K 0.42% 55
2025
Q1 		$15.6M Sell
32,141
-20,490
-39% -$9.55M 0.52% 45
2024
Q4 		$21.2M Sell
52,631
-12,624
-19% -$5.85M 0.7% 27
2024
Q3 		$30.3M Buy
65,255
+1,224
+2% +$588K 0.96% 15
2024
Q2 		$30M Sell
64,031
-721
-1% -$313K 1.02% 14
2024
Q1 		$27.1M Sell
64,752
-6,196
-9% -$2.62M 0.93% 14
2023
Q4 		$28.9M Sell
70,948
-2,044
-3% -$755K 0.98% 14
2023
Q3 		$25.4M Sell
72,992
-3,213
-4% -$1.12M 0.93% 17
2023
Q2 		$26.8M Sell
76,205
-1,470
-2% -$495K 0.98% 15
2023
Q1 		$24.5M Sell
77,675
-6,571
-8% -$1.97M 0.89% 16
2022
Q4 		$24.3M Buy
84,246
+4,524
+6% +$1.38M 0.89% 15
2022
Q3 		$23.1M Buy
79,722
+5,020
+7% +$1.44M 0.87% 17
2022
Q2 		$21.1M Buy
74,702
+2,994
+4% +$801K 0.78% 21
2022
Q1 		$18.7M Buy
71,708
+65,551
+1,065% +$15.6M 0.64% 28
2021
Q4 		$1.35M Sell
6,157
-947
-13% -$184K 0.05% 361
2021
Q3 		$1.29M Sell
7,104
-38,882
-85% -$7.59M 0.05% 372
2021
Q2 		$9.27M Sell
45,986
-605
-1% -$127K 0.31% 89
2021
Q1 		$10M Buy
46,591
+7,785
+20% +$1.71M 0.38% 77
2020
Q4 		$9.17M Buy
38,806
+11,804
+44% +$2.71M 0.38% 76
2020
Q3 		$7.35M Buy
27,002
+4,464
+20% +$1.23M 0.34% 83
2020
Q2 		$6.54M Buy
22,538
+17,032
+309% +$4.62M 0.34% 97
2020
Q1 		$1.31M Buy
5,506
+1,047
+23% +$240K 0.07% 267
2019
Q4 		$976K Buy
+4,459
New +$902K 0.05% 356

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vestcor Inc's VRTX Position: Q2 2026 in Review

Vestcor Inc reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q2 2026, selling an estimated $3M and leaving 27,242 shares worth $13.5M. The position accounts for 0.33% of the portfolio, ranked #67.

Vestcor Inc first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $30.3M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Vestcor Inc held 27,242 shares of Vertex Pharmaceuticals worth $13.5M as of Q2 2026.
  • Vestcor Inc sold 6,777 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3M.
  • Vertex Pharmaceuticals made up 0.33% of Vestcor Inc's portfolio in Q2 2026, its #67 holding.
  • Vestcor Inc first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Vestcor Inc's Vertex Pharmaceuticals position peaked at $30.3M in Q3 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vestcor Inc's 13F filing for Q2 2026, filed 11 Aug 2026.